NovoCure Limited (NVCR) — Analyst outlook / Analyst consensus target is. Based on 15 analyst ratings, the consensus is bullish — 9 Buy, 5 Hold, 1 Sell.
The consensus price target is $33.50 (low: $20.00, high: $47.00), representing an upside of 196.5% from the current price $11.30.
Analysts estimate Earnings Per Share (EPS) of $-1.30 and revenue of $0.61B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.56 vs est $-1.30 (missed -20.4%). 2025: actual $-1.22 vs est $-1.40 (beat +12.9%). Analyst accuracy: 84%.
NVCR Stock — 12-Month Price Forecast
$33.50
▲ +196.46% Upside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for NovoCure Limited, the average price target is $33.50, with a high forecast of $47.00, and a low forecast of $20.00.
The average price target represents a +196.46% change from the last price of $11.30.
Highest Price Target
$47.00
Average Price Target
$33.50
Lowest Price Target
$20.00
NVCR Analyst Ratings
Buy
Based on 15 analysts giving stock ratings to NovoCure Limited in the past 3 months
EPS Estimates — NVCR
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.56
vs Est –$1.30
▼ 16.9% off
2025
Actual –$1.22
vs Est –$1.40
▲ 14.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — NVCR
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.605B
vs Est $0.605B
▲ 0.0% off
2025
Actual $0.655B
vs Est $0.655B
▼ 0.0% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
